Vistagen Therapeutics, Inc. VTGN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-34.55
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2026 | $1.3M | -$69.7M | — | — | $35.5M |
| 2025 | $486,000 | -$51.4M | — | — | $70.4M |
| 2024 | $1.1M | -$29.4M | — | — | $114.3M |
| 2023 | -$227,000 | -$59.2M | — | — | $12.1M |
| 2022 | $1.1M | -$47.8M | — | -$45.5M | $64.7M |
| 2021 | $1.1M | -$17.9M | — | -$12.3M | $92.0M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -34.55 (distress)
- Working capital / assets 0.703
- Retained earnings / assets -9.829
- EBIT / assets -1.485
- Equity / liabilities 2.723
Source: SEC EDGAR filings · CIK 0001411685 · as of 2026-03-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.